Bridget Shields

Dr. Bridget E. Shields is the Susan Nicholas Fasciano Family Foundation Professor of Inflammatory Skin Diseases, Associate Professor, and Director of the Clinical and Translational Research Program in the Department of Dermatology at the University of Wisconsin–Madison. She completed her dermatology residency at the University of Wisconsin, where she served as Chief Resident, followed by a fellowship in Complex Medical Dermatology at the University of Pennsylvania with specialized training in granulomatous skin diseases, including cutaneous Crohn disesae. Dr. Shields directs the University of Wisconsin's specialized IBD-Dermatology clinic and serves on the inpatient dermatology consultation service, caring for patients with complex inflammatory skin disorders. She also leads the University of Wisconsin Multidisciplinary Sarcoidosis Program, fostering collaboration among clinicians and scientists to improve the understanding and treatment of systemic granulomatous disease.
As a clinician-scientist, Dr. Shields' research focuses on defining the molecular mechanisms underlying skin manifestations of IBD through spatial transcriptomics, multiomics, and translational immunology, with the goal of developing precision diagnostics and targeted therapies.
Dr. Shields has authored more than 70 peer-reviewed scientific publications and numerous invited book chapters. She is a nationally recognized speaker who has delivered invited lectures on skin manifestations of IBD and other inflammatory dermatologic disorders at regional and national scientific meetings.
Her research program has been supported by the Dermatology Foundation Medical Dermatology Career Development Award and the Ann Theodore Foundation, among other competitive funding sources.

Dr. Miguel Regueiro is the Enterprise Chief of Staff and Executive Vice President at Cleveland Clinic, and Professor in the Department of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.

Dr. Regueiro is the inaugural Chair holder of The Melody and Steve Golding Chair for Digestive Diseases. He served as the Global Chief for the Digestive Disease Institute from 2021 - 2026 before becoming Enterprise Chief of Staff. As Chief of Staff, he is responsible for shaping the healthcare strategy and vision for the national and international Cleveland Clinic sites. He oversees 6,000 physicians and 4.000 advanced practice providers across the enterprise.

Dr. Regueiro’s main clinical and research interest is Inflammatory Bowel Diseases (IBD) with a focus on the natural course and medical-surgical management of Crohn’s disease and ulcerative colitis. He leads research on postoperative prevention of Crohn’s disease, as well as developing new models of healthcare, including the first-of-its kind specialty medical home for IBD.

Corey A. Siegel, MD, MS, is the Director of the Walter and Carole Young Center for Digestive Health at the Dartmouth Hitchcock Medical Center in Lebanon, New Hampshire. He is the Constantine and Joyce Hampers Professor of Medicine and a Professor at The Dartmouth Institute for Health Policy and Clinical Practice at the Geisel School of Medicine at Dartmouth.

Dr. Siegel received his medical degree from Tufts University School of Medicine in Boston, Massachusetts. He completed his residency in internal medicine at the Dartmouth Hitchcock Medical Center where he also served as chief medical resident. He then completed a fellowship in Gastroenterology at Dartmouth Hitchcock followed by a fellowship in Inflammatory Bowel Disease at Massachusetts General Hospital in Boston.

Dr. Siegel’s research interests include understanding risk/benefit tradeoffs in IBD, developing models to predict outcomes in Crohn’s disease, creating tools to facilitate shared decision making, expanding telemedicine services to patients with IBD living in rural locations, and improving the quality of care delivered to patients with IBD. He has been funded by the NIH, AHRQ, the Crohn’s and Colitis Foundation, and the Leona M. and Harry B. Helmsley Charitable Trust for this work. Dr. Siegel is the founder of the BRIDGe group, an international research collaborative of IBD investigators. Dr. Siegel was inducted into the International Organization for the Study of IBD (IOIBD) in 2013 and he received the Sherman Prize in 2023. He lives in Hanover, New Hampshire with his wife and three boys.

Dr. Sara Horst MD, MPH, FACG, AGAF is a Professor in the division of Gastroenterology, Hepatology, & Nutrition at Vanderbilt University Medical Center. Dr. Horst completed her medical school and residency training at The Ohio State University and then went to Vanderbilt University Medical Center for Gastroenterology Fellowship and to obtain her Masters of Public Health. She joined the faculty at Vanderbilt University Medical Center in 2011. She is involved in clinical care of complex IBD care, complex amyloid care, clinical research, and teaching and mentoring medical students and housestaff. She is the medical director for VUMC Specialty Pharmacy, VUMC Telehealth director, and VUMC Associate Vice Chair of Clinical Affairs for Dept of Medicine. Her research interests involve enhancing EHR efficiencies in the care of IBD, telehealth in IBD, and medication adherence in IBD. She has extensively published in peer reviewed journals. She is also involved in clinical care improvement as an EPIC Physician Builder and is on the National EPIC GI Steering Board. She is an associate editor for American Journal of Gastroenterology.

Edward V. Loftus, Jr. is a gastroenterologist who specializes in the care of patients with complex Crohn's disease and ulcerative colitis. He is the Maxine and Jack Zarrow Family Professor of Gastroenterology Specifically in IBD at Mayo Clinic College of Medicine and Science in Rochester, Minnesota, USA. He developed a population-based cohort of inflammatory bowel disease patients which has resulted in over 50 peer-reviewed publications on the epidemiology and natural history of IBD. Professor Loftus has published over 500 original articles, book chapters, or editorials and more than 750 abstracts. He was awarded AGA’s Distinguished Clinician Award and the IMIBD section’s Research Mentor Award in 2019. He has also been awarded the Mayo Department of Medicine Laureate Award twice and the Outstanding Mentorship Award in Research. Professor Loftus has been the principal investigator on several funded studies focusing on the epidemiology and natural history of inflammatory bowel disease and has served as the local PI on multiple clinical trials of investigational agents for IBD. He serves on the steering committees of several clinical development programs in IBD. In the past he has served as Associate Editor for American Journal of Gastroenterology and Inflammatory Bowel Diseases, and currently serves as Associate Editor for Clinical Gastroenterology and Hepatology.

Laura Raffals, MD, MS, FACG is Professor of Medicine, Vice Chair, Department of Medicine at Mayo Clinic, Rochester, MN. She received her Masters in Health Studies and completed her gastroenterology fellowship training at the University of Chicago, and for six years was a member of the faculty. In 2011, she joined the Gastroenterology and Hepatology Division at Mayo Clinic. Dr. Raffals’ clinical and research interests have focused on inflammatory bowel disease with a focus on pouch disorders, exploring the intersection of pouch motility disorders and pouch inflammation. She is the co-principal investigator for the Crohn’s and Colitis Foundation SPARC IBD, a national prospective adult research cohort with IBD study and has published broadly on topics in inflammatory bowel disease.

Bruce Sands, MD, MS is the Dr. Burrill B. Crohn Professor of Medicine at the Icahn School of Medicine at Mount Sinai, New York, NY. Dr. Sands is an expert in the management of IBD and has earned an international reputation for his care of patients with complex and refractory disease. Dr. Sands was awarded his BA and MD from Boston University, and trained in internal medicine at the Hospital of the University of Pennsylvania. After completing GI fellowship at the Massachusetts General Hospital, he joined the faculty of Harvard Medical School and served as the Acting Chief of the Gastrointestinal Unit at MGH before moving to Mount Sinai in 2010 as Chief of the Dr. Henry D. Janowitz Division of Gastroenterology. Dr. Sands is widely recognized for his innovative treatment of IBD and for his clinical investigations of new therapeutics. Dr. Sands' research also explores IBD epidemiology and includes the creation of a population-based cohort of IBD in Rhode Island. Dr. Sands is a past chair of the Clinical Research Alliance of the Crohn's & Colitis Foundation of America and served as Chair of the Immunology, Microbiology and Inflammatory Bowel Disease Section of the American Gastroenterological Association. Additionally, Dr. Sands was the Chair of the International Organization for the Study of IBD (IOIBD). In 2016 Dr. Sands was awarded the Dr. Henry Janowitz Lifetime Achievement Award from the Crohn’s & Colitis Foundation of America, that organization’s highest honor.

Dr. Bridget E. Shields is the Susan Nicholas Fasciano Family Foundation Professor of Inflammatory Skin Diseases, Associate Professor, and Director of the Clinical and Translational Research Program in the Department of Dermatology at the University of Wisconsin–Madison. She completed her dermatology residency at the University of Wisconsin, where she served as Chief Resident, followed by a fellowship in Complex Medical Dermatology at the University of Pennsylvania with specialized training in granulomatous skin diseases, including cutaneous Crohn disesae. Dr. Shields directs the University of Wisconsin's specialized IBD-Dermatology clinic and serves on the inpatient dermatology consultation service, caring for patients with complex inflammatory skin disorders. She also leads the University of Wisconsin Multidisciplinary Sarcoidosis Program, fostering collaboration among clinicians and scientists to improve the understanding and treatment of systemic granulomatous disease.
As a clinician-scientist, Dr. Shields' research focuses on defining the molecular mechanisms underlying skin manifestations of IBD through spatial transcriptomics, multiomics, and translational immunology, with the goal of developing precision diagnostics and targeted therapies.
Dr. Shields has authored more than 70 peer-reviewed scientific publications and numerous invited book chapters. She is a nationally recognized speaker who has delivered invited lectures on skin manifestations of IBD and other inflammatory dermatologic disorders at regional and national scientific meetings.
Her research program has been supported by the Dermatology Foundation Medical Dermatology Career Development Award and the Ann Theodore Foundation, among other competitive funding sources.

Dr. Cheifetz is Director of the Center for Inflammatory Bowel Disease and Medical Director of Infusion Services at Beth Israel Deaconess Medical Center and Professor of Medicine at Harvard Medical School. He is also Director of the Harvard Medical School Gastroenterology Clerkship Elective and Associate Director of the Advanced Fellowship in Inflammatory Bowel Disease at Beth Israel Deaconess Medical Center.
Dr. Cheifetz specializes in the treatment of Crohn’s disease, ulcerative colitis, and other inflammatory bowel diseases. In addition to his clinical work, he is involved in multiple research projects relating to IBD and has published over 250 articles and chapters on the subject. His research currently focuses on optimizing the use of biologics through the proactive use of drug concentrations and antibodies, and he has published extensively in this area. Dr. Cheifetz was the first to demonstrate that proactive monitoring of infliximab and adalimumab concentrations and dosing to a therapeutic window improves outcomes when compared to standard of care. Dr. Cheifetz lectures nationally and internationally on IBD. Dr. Cheifetz is also actively involved in teaching and mentoring medical students, residents, and fellows, and is proud to have trained numerous physicians who now specialize in IBD and direct their own centers.

Dr. Bridget E. Shields is the Susan Nicholas Fasciano Family Foundation Professor of Inflammatory Skin Diseases, Associate Professor, and Director of the Clinical and Translational Research Program in the Department of Dermatology at the University of Wisconsin–Madison. She completed her dermatology residency at the University of Wisconsin, where she served as Chief Resident, followed by a fellowship in Complex Medical Dermatology at the University of Pennsylvania with specialized training in granulomatous skin diseases, including cutaneous Crohn disesae. Dr. Shields directs the University of Wisconsin's specialized IBD-Dermatology clinic and serves on the inpatient dermatology consultation service, caring for patients with complex inflammatory skin disorders. She also leads the University of Wisconsin Multidisciplinary Sarcoidosis Program, fostering collaboration among clinicians and scientists to improve the understanding and treatment of systemic granulomatous disease.
As a clinician-scientist, Dr. Shields' research focuses on defining the molecular mechanisms underlying skin manifestations of IBD through spatial transcriptomics, multiomics, and translational immunology, with the goal of developing precision diagnostics and targeted therapies.
Dr. Shields has authored more than 70 peer-reviewed scientific publications and numerous invited book chapters. She is a nationally recognized speaker who has delivered invited lectures on skin manifestations of IBD and other inflammatory dermatologic disorders at regional and national scientific meetings.
Her research program has been supported by the Dermatology Foundation Medical Dermatology Career Development Award and the Ann Theodore Foundation, among other competitive funding sources.

Oriana M. Damas, MD, MSCTI, is an Associate Professor of Medicine at the University of Miami Miller School of Medicine. She also serves as the Director of Translational Studies for the Crohn’s and Colitis Center. Dr. Damas earned her medical degree from the University of Miami and completed her training in internal medicine and gastroenterology at the University of Miami and Jackson Memorial Hospital.

Her clinical practice and research focus on the care of patients with inflammatory bowel disease (IBD). Dr. Damas has conducted extensive research on environmental factors and the epidemiology of IBD. Her contributions to the field have earned her accolades, including the DREAM Award in recognition of her work with the Hispanic IBD community.

Dr. Damas has significant experience in running clinical trials, including innovative dietary trials, aimed at improving the quality of life for patients with IBD through lifestyle and dietary modifications. She is an NIH-funded researcher and currently serves as the principal investigator for a study developing an anti-inflammatory South Florida diet for IBD patients, which incorporates elements of traditional Latin foods from the region.

She has authored numerous original research articles, and she serves on the Editorial Boards of the prestigious Gastroenterology journal and Crohn’s & Colitis 360. In addition to her research, Dr. Damas is recognized as a national and international leader in her field. She is frequently invited to speak at national and international conferences and is an active member of the AGA n and the Crohn’s & Colitis Foundation.

Millie D. Long MD, MPH earned her doctor of medicine degree at the University of Virginia. She completed a residency and chief residency in internal medicine at the University of Alabama at Birmingham. She then completed a gastroenterology fellowship at University of North Carolina. She also completed a fellowship in preventive medicine and a masters of public health in epidemiology at the Gillings School of Public Health. She is board certified in internal medicine, preventive medicine, and gastroenterology. She is currently Professor of Medicine in the Division of Gastroenterology and Hepatology at the University of North Carolina, as well as Chief of the Division.

Dr. Long’s clinical practice is at the UNC Multidisciplinary Inflammatory Bowel Diseases (IBD) center. Her research interests include prevention of complications of IBD, women’s health and clinical epidemiology. Dr. Long has contributed over 200 peer-reviewed publications, book chapters, and review articles to the literature. She co-authored the 2025 ACG ulcerative colitis guidelines. She serves Co-Editor in Chief of the American Journal of Gastroenterology.

Dr. Long is a fellow of the American College of Gastroenterology where she is a member of the Board of Trustees. She is also a fellow of the American Gastroenterological Association and a member of the Crohn’s and Colitis Foundation. Recipient of the 2024 Sherman Prize for Excellence in Crohn’s and Colitis. She is a member of the International Organization for the Study of IBD.

Jason Schairer is the Director of the Henry Ford IBD Center in Michigan. His interests include Interventional IBD with a focus on stricturotomy, addressing health care inequity, intimacy and sex in IBD, and improving medical education for providers of all levels. He received his medical degree from Wayne Statue University, and went on to complete a fellowship in gastroenterology at Providence Hospital in Michigan. He previously served as the Associate Program Director of the Henry Ford Gastroenterology and Hepatology fellowship, and continues to be involved in fellow education of IBD across the state of Michigan. He has been recognized for his teaching efforts, high quality care of IBD patients and contributions to patient education. He has presented at ESCCO, AIBD and DDW. He is Vice President of the Interventional IBD Special Interest Group of ASGE. He is President of the Oakland County Medical Society. He is also active on social media including Twitter and Youtube.

Dr. Cheifetz is Director of the Center for Inflammatory Bowel Disease and Medical Director of Infusion Services at Beth Israel Deaconess Medical Center and Professor of Medicine at Harvard Medical School. He is also Director of the Harvard Medical School Gastroenterology Clerkship Elective and Associate Director of the Advanced Fellowship in Inflammatory Bowel Disease at Beth Israel Deaconess Medical Center.
Dr. Cheifetz specializes in the treatment of Crohn’s disease, ulcerative colitis, and other inflammatory bowel diseases. In addition to his clinical work, he is involved in multiple research projects relating to IBD and has published over 250 articles and chapters on the subject. His research currently focuses on optimizing the use of biologics through the proactive use of drug concentrations and antibodies, and he has published extensively in this area. Dr. Cheifetz was the first to demonstrate that proactive monitoring of infliximab and adalimumab concentrations and dosing to a therapeutic window improves outcomes when compared to standard of care. Dr. Cheifetz lectures nationally and internationally on IBD. Dr. Cheifetz is also actively involved in teaching and mentoring medical students, residents, and fellows, and is proud to have trained numerous physicians who now specialize in IBD and direct their own centers.

Dr. Bridget E. Shields is the Susan Nicholas Fasciano Family Foundation Professor of Inflammatory Skin Diseases, Associate Professor, and Director of the Clinical and Translational Research Program in the Department of Dermatology at the University of Wisconsin–Madison. She completed her dermatology residency at the University of Wisconsin, where she served as Chief Resident, followed by a fellowship in Complex Medical Dermatology at the University of Pennsylvania with specialized training in granulomatous skin diseases, including cutaneous Crohn disesae. Dr. Shields directs the University of Wisconsin's specialized IBD-Dermatology clinic and serves on the inpatient dermatology consultation service, caring for patients with complex inflammatory skin disorders. She also leads the University of Wisconsin Multidisciplinary Sarcoidosis Program, fostering collaboration among clinicians and scientists to improve the understanding and treatment of systemic granulomatous disease.
As a clinician-scientist, Dr. Shields' research focuses on defining the molecular mechanisms underlying skin manifestations of IBD through spatial transcriptomics, multiomics, and translational immunology, with the goal of developing precision diagnostics and targeted therapies.
Dr. Shields has authored more than 70 peer-reviewed scientific publications and numerous invited book chapters. She is a nationally recognized speaker who has delivered invited lectures on skin manifestations of IBD and other inflammatory dermatologic disorders at regional and national scientific meetings.
Her research program has been supported by the Dermatology Foundation Medical Dermatology Career Development Award and the Ann Theodore Foundation, among other competitive funding sources.

Oriana M. Damas, MD, MSCTI, is an Associate Professor of Medicine at the University of Miami Miller School of Medicine. She also serves as the Director of Translational Studies for the Crohn’s and Colitis Center. Dr. Damas earned her medical degree from the University of Miami and completed her training in internal medicine and gastroenterology at the University of Miami and Jackson Memorial Hospital.

Her clinical practice and research focus on the care of patients with inflammatory bowel disease (IBD). Dr. Damas has conducted extensive research on environmental factors and the epidemiology of IBD. Her contributions to the field have earned her accolades, including the DREAM Award in recognition of her work with the Hispanic IBD community.

Dr. Damas has significant experience in running clinical trials, including innovative dietary trials, aimed at improving the quality of life for patients with IBD through lifestyle and dietary modifications. She is an NIH-funded researcher and currently serves as the principal investigator for a study developing an anti-inflammatory South Florida diet for IBD patients, which incorporates elements of traditional Latin foods from the region.

She has authored numerous original research articles, and she serves on the Editorial Boards of the prestigious Gastroenterology journal and Crohn’s & Colitis 360. In addition to her research, Dr. Damas is recognized as a national and international leader in her field. She is frequently invited to speak at national and international conferences and is an active member of the AGA n and the Crohn’s & Colitis Foundation.

Millie D. Long MD, MPH earned her doctor of medicine degree at the University of Virginia. She completed a residency and chief residency in internal medicine at the University of Alabama at Birmingham. She then completed a gastroenterology fellowship at University of North Carolina. She also completed a fellowship in preventive medicine and a masters of public health in epidemiology at the Gillings School of Public Health. She is board certified in internal medicine, preventive medicine, and gastroenterology. She is currently Professor of Medicine in the Division of Gastroenterology and Hepatology at the University of North Carolina, as well as Chief of the Division.

Dr. Long’s clinical practice is at the UNC Multidisciplinary Inflammatory Bowel Diseases (IBD) center. Her research interests include prevention of complications of IBD, women’s health and clinical epidemiology. Dr. Long has contributed over 200 peer-reviewed publications, book chapters, and review articles to the literature. She co-authored the 2025 ACG ulcerative colitis guidelines. She serves Co-Editor in Chief of the American Journal of Gastroenterology.

Dr. Long is a fellow of the American College of Gastroenterology where she is a member of the Board of Trustees. She is also a fellow of the American Gastroenterological Association and a member of the Crohn’s and Colitis Foundation. Recipient of the 2024 Sherman Prize for Excellence in Crohn’s and Colitis. She is a member of the International Organization for the Study of IBD.

Jason Schairer is the Director of the Henry Ford IBD Center in Michigan. His interests include Interventional IBD with a focus on stricturotomy, addressing health care inequity, intimacy and sex in IBD, and improving medical education for providers of all levels. He received his medical degree from Wayne Statue University, and went on to complete a fellowship in gastroenterology at Providence Hospital in Michigan. He previously served as the Associate Program Director of the Henry Ford Gastroenterology and Hepatology fellowship, and continues to be involved in fellow education of IBD across the state of Michigan. He has been recognized for his teaching efforts, high quality care of IBD patients and contributions to patient education. He has presented at ESCCO, AIBD and DDW. He is Vice President of the Interventional IBD Special Interest Group of ASGE. He is President of the Oakland County Medical Society. He is also active on social media including Twitter and Youtube.

Dr. Hanauer is the Clifford Joseph Barborka Professor of Medicine and Medical Director of the Digestive Health Center at Northwestern University’s Feinberg School of Medicine since 2014. Dr. Hanauer received his medical degree from the University of Illinois Chicago, and he completed his residency in internal medicine and a fellowship in gastroenterology at the University of Chicago in 1982. In 2014, Dr. Hanauer was named the Medical Director of the Digestive Health Center at Northwestern Medicine and the Clifford Joseph Barborka Professor of Medicine in the Northwestern University’s Feinberg School of Medicine, where he continues to treat IBD patients and conducts research into new therapies.

Dr. Hanauer is a Fellow and past President of the American College of Gastroenterology (ACG) and the former Chair of the American Gastroenterological Association’s Inflammation, Immunology, and IBD Section. In October 2020, received the Master of the American College of Gastroenterology.

Internationally recognized expert on the treatment of inflammatory bowel disease (IBD), former chair of the FDA Gastrointestinal Drugs Advisory Committee and advisor on the development of multiple leading IBD drugs. Dr. Hanauer has expertise in designing and leading clinical studies for IBD related therapies and has acted as a clinical investigator and/or advisor to pharmaceutical companies in the development of most of the leading IBD therapies.

Dr. Hanauer has authored over 500 peer-reviewed journal articles and numerous books and book chapters, abstracts, monographs, and editorials. He has been a reviewer for NEJM, Annals of Internal Medicine, Lancet, Gastroenterology and numerous specialty journals.

Neilanjan Nandi, MD, FACG, AGAF, FCCF, FACP is an Associate Professor of Clinical Medicine at the Perelman School of Medicine, University of Pennsylvania and is the Co-Section Head and Direcotr of Clinical Operations of the University of Pennsylvania Inflammatory Bowel Disease Program. Dr. Nandi specializes in the complex management of Crohn's disease, Ulcerative Colitis and recurrent C. difficile infection (C difficile). He has also authored numerous abstracts, publications and book chapters on the diagnosis and management of IBD, C difficile and various viral, parasitic, mycobacterial and bacterial infections of the GI tract. Aligning with his interests, Dr. Nandi has conducted several clinical trials focused on the clinical impact of stool derived microbiome therapies in C difficile and IBD. Dr. Nandi servies on the Philadelphia/Delaware Valley Crohn's & Colitis Foundation (CCF) Executive Council and on the Medical Advisory Board of the United Ostomy Associates of America (UOAA). He is a founding non-profit board member and Chair of the South Asian IBD Alliance (SAIA) which elevates culturally competent care in South Asian IBD. He has been recognized with the 2019 Philly Take STeps Physician Hero, the 2022 CCF's National Chairman’s Citation Award and the 2024 CCF's Gold Medallion Physician Award. He is the honored recipient of the 2023 Sidney Cohen GI Faculty Teaching Award and the 2024 Radhika Srinivasan GI Faculty award for Professionalism and Humanism at the Perelman School of Medicine.

Dr. Bridget E. Shields is the Susan Nicholas Fasciano Family Foundation Professor of Inflammatory Skin Diseases, Associate Professor, and Director of the Clinical and Translational Research Program in the Department of Dermatology at the University of Wisconsin–Madison. She completed her dermatology residency at the University of Wisconsin, where she served as Chief Resident, followed by a fellowship in Complex Medical Dermatology at the University of Pennsylvania with specialized training in granulomatous skin diseases, including cutaneous Crohn disesae. Dr. Shields directs the University of Wisconsin's specialized IBD-Dermatology clinic and serves on the inpatient dermatology consultation service, caring for patients with complex inflammatory skin disorders. She also leads the University of Wisconsin Multidisciplinary Sarcoidosis Program, fostering collaboration among clinicians and scientists to improve the understanding and treatment of systemic granulomatous disease.
As a clinician-scientist, Dr. Shields' research focuses on defining the molecular mechanisms underlying skin manifestations of IBD through spatial transcriptomics, multiomics, and translational immunology, with the goal of developing precision diagnostics and targeted therapies.
Dr. Shields has authored more than 70 peer-reviewed scientific publications and numerous invited book chapters. She is a nationally recognized speaker who has delivered invited lectures on skin manifestations of IBD and other inflammatory dermatologic disorders at regional and national scientific meetings.
Her research program has been supported by the Dermatology Foundation Medical Dermatology Career Development Award and the Ann Theodore Foundation, among other competitive funding sources.

Dr. Miguel Regueiro is the Enterprise Chief of Staff and Executive Vice President at Cleveland Clinic, and Professor in the Department of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.

Dr. Regueiro is the inaugural Chair holder of The Melody and Steve Golding Chair for Digestive Diseases. He served as the Global Chief for the Digestive Disease Institute from 2021 - 2026 before becoming Enterprise Chief of Staff. As Chief of Staff, he is responsible for shaping the healthcare strategy and vision for the national and international Cleveland Clinic sites. He oversees 6,000 physicians and 4.000 advanced practice providers across the enterprise.

Dr. Regueiro’s main clinical and research interest is Inflammatory Bowel Diseases (IBD) with a focus on the natural course and medical-surgical management of Crohn’s disease and ulcerative colitis. He leads research on postoperative prevention of Crohn’s disease, as well as developing new models of healthcare, including the first-of-its kind specialty medical home for IBD.